Effectiveness and Safety of Cellbooster Hair in Healthy Subjects
NCT07929857, Not applicable, Not yet recruiting, Suisselle
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effectiveness and Safety of Cellbooster Hair in Healthy Subjects | ClinicalTrials.gov |
| NCT number | NCT07929857 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 55 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Suisselle | ClinicalTrials.gov |
| Conditions | Hair and Scalp Health | ClinicalTrials.gov |
| Interventions | Scalp booster injection (CBH) | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from baseline of hair density (total number of hair in the studied zone) at Day 130 evaluated by Phototrichogram (PTG) analysis | Day 130 | ClinicalTrials.gov | |
| Secondary | Change from baseline of hair diameter at Day 130 evaluated by Phototrichogram (PTG) analysis | Day 130 | ClinicalTrials.gov | |
| Secondary | Change from baseline of hair loss at Day 130 evaluated by Phototrichogram (PTG) analysis : percentage of telogen hair (%T) | Day 130 | ClinicalTrials.gov | |
| Secondary | Change from baseline of hair loss at Day 130 evaluated by Phototrichogram (PTG) analysis : anagen hair density (DA), telogen hair density (DT) | Day 130 | ClinicalTrials.gov | |
| Secondary | Change from baseline of hair loss at Day 130 evaluated by Phototrichogram (PTG) analysis : anagen to telogen ratio (DA/DT) | Day 130 | ClinicalTrials.gov | |
| Secondary | Change from baseline of hair average roughness (Ra), quadratic mean (Rq), maximum relief amplitude (Rt) and average relief (Rz) at Day 130 evaluated by MiniSurf® (only on subjects with hair length>10 cm). | Day 130 | ClinicalTrials.gov | |
| Secondary | Change from baseline of scalp skin hydration at Day 35 and Day 130 evaluated by Corneometer® on shaved area. | Day 35 and Day 130 | ClinicalTrials.gov | |
| Secondary | Change from baseline of scalp skin trans epidermal water loss (TEWL) at Day 35 and Day 130 evaluated by Aquaflux® on shaved area. | Day 35 and Day 130 | ClinicalTrials.gov | |
| Secondary | Change from baseline of scalp dermis thickness and density (ratio non-echogenic surface/total surface) at Day 35 and Day 130 evaluated by DermaScan® 2D on shaved area. | Day 35 and Day 130 | ClinicalTrials.gov | |
| Secondary | Proportion of subjects having an improvement with CBH treatment as assessed by the investigator at Day 35 and Day 130, using the Investigator Global Assessment (IGA). | Day 35 and Day 130 | An improvement is defined as subject having a score "very much improved", "much improved" or "improved" on the Investigator Global Assessment (IGA) 4-grade scale: 1: Strongly disagree 2: Disagree 3: Agree 4: Strongly | ClinicalTrials.gov |
| Secondary | Illustration of the device effect on hair loss with standardized photos of the vertex and after standardized shampoo/cut/brush at Day 0, Day 35 and Day 130. | Day 0, Day 35 and Day 130 | ClinicalTrials.gov | |
| Secondary | Degree of satisfaction of the injectors through the answers to a subjective evaluation questionnaire completed for each subject after each three injection session (Day 28 and Day 70). | Day 28 and Day 70 | For each question, the percentage of answers "agree" or "totally agree" will be computed 5-grade scale: Strongly disagree ; 1 : Disagree ; 2 : Neither agree nor disagree ; 3 : Agree ; 4 : Strongly agree | ClinicalTrials.gov |
| Secondary | Degree of satisfaction of the subjects through the answers to a subjective evaluation questionnaire at Day 35 and Day 130. For each question, the percentage of subject satisfied, (percentages of answers "agree" or "totally agree") will be computed. | Day 35 and Day 130 | ClinicalTrials.gov | |
| Secondary | Number of Injection Site Reactions (ISRs) by the investigator on the scalp, before and immediately after each injection session (Day 0, Day 14, Day 28, Day 35, Day 42, Day 56, Day 70 and Day 130). | Day 0, Day 14, Day 28, Day 35, Day 42, Day 56, Day 70 and Day 130 | ClinicalTrials.gov | |
| Secondary | Number of adverse events (AEs) and concomitant treatments during the study. | Day 0 - Day 130 | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)